Pembrolizumab Indications in Breast Cancer
Pembrolizumab is FDA-approved for two distinct breast cancer indications: (1) high-risk early-stage triple-negative breast cancer (TNBC) as neoadjuvant-adjuvant therapy combined with chemotherapy, and (2) locally recurrent unresectable or metastatic TNBC with PD-L1 CPS ≥10 in combination with chemotherapy. 1
Early-Stage Triple-Negative Breast Cancer
Standard Indication
For patients with high-risk early-stage TNBC, pembrolizumab is given:
- Neoadjuvant phase: Combined with chemotherapy (paclitaxel/carboplatin followed by doxorubicin or epirubicin plus cyclophosphamide)
- Surgery: Definitive surgical resection
- Adjuvant phase: Continued as single-agent pembrolizumab for up to 9 cycles 1
This regimen is based on the KEYNOTE-522 trial, which demonstrated a pathologic complete response (pCR) rate of 64.8% versus 51.2% with chemotherapy alone, and significantly improved event-free survival (HR 0.63) 2, 3. The NCCN Guidelines designate this as the current standard of care for stage II-III TNBC 4.
Alternative Anthracycline-Free Regimen
For patients who cannot receive anthracyclines, the NCCN panel includes docetaxel/carboplatin/pembrolizumab as "useful in certain circumstances" based on the NeoPACT study (pCR rate 58%) 4. However, this should not routinely substitute for the KEYNOTE-522 regimen, particularly in patients with axillary lymph node metastases where the anthracycline-containing regimen appears more effective 4.
Important Caveats for Early-Stage Disease
- No PD-L1 testing required: Unlike metastatic disease, early-stage TNBC patients benefit from pembrolizumab regardless of PD-L1 status 2
- High toxicity burden: Real-world evidence shows 65% experience immune-related adverse events (irAEs), with 20% experiencing grade ≥3 irAEs, and 47% requiring treatment discontinuation 5
- Surgical safety: Adding pembrolizumab does not adversely impact surgical outcomes, timing, or safety 6
Metastatic Triple-Negative Breast Cancer
PD-L1 Testing Requirement
Patients with locally recurrent unresectable or metastatic TNBC must undergo PD-L1 testing using the FDA-approved 22C3 companion assay before receiving pembrolizumab plus chemotherapy 7. Treatment is indicated only when PD-L1 CPS ≥10 1.
Treatment Regimen
Pembrolizumab 200 mg every 3 weeks combined with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine-carboplatin) 7.
Evidence Base
The KEYNOTE-355 trial showed that in patients with PD-L1 CPS ≥10:
- Median overall survival: 23.0 months versus 16.1 months (HR 0.73, P=0.0185) 8
- Median progression-free survival: 9.7 months versus 5.6 months (HR 0.65) 7
Critical point: Patients with PD-L1 CPS 1-9 did NOT meet statistical significance for benefit and should not receive pembrolizumab 7, 8.
PD-L1 Testing Technical Details
- Specific assay required: 22C3 companion diagnostic
- CPS calculation: (PD-L1 staining tumor cells + lymphocytes + macrophages) ÷ total viable tumor cells × 100
- Different assays yield different results: Do not use assays from other immunotherapy trials (e.g., atezolizumab trials) 7
Additional Rare Indication
For metastatic breast cancer with MSI-H/dMMR status, pembrolizumab monotherapy may be considered as a tumor-agnostic indication, though this is extremely rare in breast cancer 7, 1.
What Pembrolizumab is NOT Indicated For
- Pembrolizumab monotherapy failed in previously treated metastatic TNBC (KEYNOTE-119 trial showed no OS benefit even in PD-L1+ patients) 7
- Hormone receptor-positive breast cancer: While the KEYNOTE-756 trial showed improved pCR rates (24.3% vs 15.6%) in ER+/HER2- disease, this is not yet FDA-approved and event-free survival data remain immature 9
- HER2-positive breast cancer: No approved indication
Common Pitfalls to Avoid
- Do not use pembrolizumab in metastatic TNBC without confirming PD-L1 CPS ≥10 using the 22C3 assay
- Do not substitute the anthracycline-free regimen routinely in early-stage disease, especially with node-positive disease
- Do not assume all PD-L1 assays are equivalent—the specific companion diagnostic matters
- Prepare patients for high rates of irAEs and unplanned medical contacts, particularly in the neoadjuvant setting where real-world toxicity exceeds trial data 5